Loading patent…
AssigneeScantibodies Laboratory, Inc.
InventorThomas L. Cantor
Estimating the term…
The present invention relates to a novel method for treating a patient that has osteoporosis and the patient may be having administered cyclase activating parathyroid hormone (CAP) or analogues. The patient receives an administration of a cyclase inhibiting parathyroid hormone peptide (CIP) having an amino acid sequence from between (SEQ ID No.1 [PTH2-84]) and (SEQ ID No. 2 [PTH34-84]), (preferably (SEQ ID No.3 [PTH3-84]) and (SEQ ID No. 4 [PTH28-84])), or a conservatively substituted variant thereof exhibiting parathyroid hormone (PTH) antagonist activity in a therapeutically effective, but non-toxic amount that reduces the occurrence of hypercalcemia or osteosarcoma in the patient resulting from the administration of CAP, and yet, through a CAP rebound effect, is effective in itself in the treatment of osteoporosis.
A method for treating a patient that has osteoporosis and is being administered cyclase activating parathyroid hormone (CAP) or analogues thereof comprising also administering a cyclase inhibiting parathyroid hormone peptide (CIP) having an amino acid sequence from between (SEQ ID No.1 [PTH2-84]) and (SEQ ID No. 2 [PTH34-84]) or a conservatively substituted variant thereof exhibiting parathyroid hormone (PTH) antagonist activity in a therapeutically effective, but non-toxic amount that reduces the occurrence of hypercalcemia or osteosarcoma in the patient resulting from the administration of CAP.
A method for treating a patient that has osteoporosis comprising administering a cyclase inhibiting parathyroid hormone peptide (CIP) having an amino acid sequence from between (SEQ ID No.1 [PTH2-84]) and (SEQ ID No. 2 [PTH34-84]) or a conservatively substituted variant thereof exhibiting parathyroid hormone (PTH) antagonist activity in a therapeutically effective, but non-toxic amount that reduces the occurrence of hypercalcemia or osteosarcoma in the patient resulting from the administration of CAP.
Dependencies are inferred from the claim text.